global clinical trial consulting LLC

385 fort washington ave #63
new york, new york 10033

NYS Entity Status
ACTIVE

NYS Filing Date
AUGUST 05, 2013

NYS DOS ID#
4440841

County
NEW YORK

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2013 - GLOBAL CLINICAL TRIAL CONSULTING LLC









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Celgene Builds Up Cancer Drug Pipeline With BeiGene Deal
    By Frank Vinluan - Thursday Jul 6, 2017

    Celgene wants a shot at a bigger slice of the global cancer drug market, and the company is turning to China to do it. Summit, NJ-based Celgene has reached a deal with BeiGene, based in Beijing, for rights to a cancer immunotherapy still in clinical trials. The deal announced late Wednesday calls for Celgene (NASDAQ: […]

    Source: Xconomy New York
  • Dermira Commits $135M for Global Rights to Roche Eczema Drug
    By Frank Vinluan - Tuesday Aug 8, 2017

    Skin treatments developer Dermira is adding another experimental drug to its pipeline that it plans to test as a potential treatment for eczema, through a deal announced this morning with healthcare giant Roche. But in picking up the global rights to lebrikizumab, Menlo Park, CA-based Dermira (NASDAQ: DERM) is entering a suddenly crowded field of […]

    Source: Xconomy New York
  • FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
    By Ben Fidler - Tuesday Aug 29, 2017

    The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]

    Source: Xconomy New York
  • Acorda Scraps One Parkinson’s Drug, Puts Its Cash Behind Another
    By Frank Vinluan - Monday Nov 20, 2017

    Acorda Therapeutics said Monday that it will stop work on an experimental treatment for Parkinson’s disease, spelling the end for a drug the Ardsley, NY, company added to its pipeline last year in a $363 million deal. The announcement follows the recent emergence of safety problems for the Acorda (NASDAQ: ACOR) drug, tozadenant. Acorda said […]

    Source: Xconomy New York
  • FDA Halts Merck’s Multiple Myeloma Trials After Patient Deaths
    By Frank Vinluan - Wednesday Jul 5, 2017

    Nearly a month after Merck paused enrollment in three clinical trials in multiple myeloma to gather more information about patient deaths, the FDA has now put a stop to those studies altogether. Merck (NYSE: MRK) said Wednesday that the FDA has placed a complete hold on two Phase 3 trials testing its immunotherapy drug pembrolizumab […]

    Source: Xconomy New York